GlassScriptPhysician profile
Jonathan M Belk
NPI 1508213786
$2,417.16
in general payments reported to CMS, 2019-2025
37 companies · $419 in 2025
The $419 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $79.10 · 2021: $515 · 2022: $684 · 2023: $484 · 2024: $236 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,124 · Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,124.05 |
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $285.56 | 2021-2025 | Ultomiris |
| Biogen, INC. | $259.60 | 2020-2024 | Tysabri, Vumerity |
| Novartis Pharmaceuticals Corporation | $229.33 | 2021-2025 | |
| Abbvie INC. | $222.63 | 2021-2023 | Botox, Ubrelvy |
| Lilly USA, LLC | $219.00 | 2021-2025 | Kisunla, Amyvid |
| Livanova USA, INC. | $91.98 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Genentech USA, INC. | $90.08 | 2021-2023 | Ocrevus |
| Teva Pharmaceuticals USA, INC. | $70.27 | 2021-2023 | Ajovy |
| Acadia Pharmaceuticals INC | $69.28 | 2020-2023 | Nuplazid |
| Biohaven Pharmaceuticals, INC. | $66.65 | 2021 | |
| Amneal Pharmaceuticals LLC | $61.69 | 2022 | |
| Ucb, INC. | $59.81 | 2021-2025 | Rystiggo |
| Merz Pharmaceuticals, LLC | $58.53 | 2022-2023 | Xeomin |
| Neurelis, INC. | $54.15 | 2021-2023 | Valtoco |
| Amgen INC. | $48.48 | 2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $44.59 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.34 | 2022 | |
| Avanir Pharmaceuticals, INC. | $37.31 | 2020-2021 | |
| Genzyme Corporation | $34.86 | 2022 | |
| Argenx US, INC. | $28.53 | 2023 | Vyvgart |
| Sunovion Pharmaceuticals INC. | $28.42 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $27.13 | 2020-2022 | |
| Allergan, INC. | $26.53 | 2020-2022 | |
| Acorda Therapeutics, INC | $25.31 | 2021 | |
| Csl Behring | $25.06 | 2023 | Hizentra |
| Sumitomo Pharma America, INC. | $24.16 | 2023 | Aptiom |
| Tanabe Pharma America, INC. | $22.06 | 2022 | |
| Pfizer INC. | $21.29 | 2023 | |
| Medtronic, INC. | $21.01 | 2024 | Percept PC Brainsense |
| Averitas Pharma INC. | $20.24 | 2023 | Qutenza |
| Kyowa Kirin, INC. | $16.79 | 2023 | Nourianz |
| Emd Serono, INC. | $16.46 | 2021 | |
| Eisai INC. | $15.10 | 2022 | |
| Horizon Therapeutics Plc | $14.27 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.10 | 2022 | |
| Avion Pharmaceuticals | $13.35 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Belk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.